Rebif has much better control over MRI lesion progression and is indicated for reducing progression of disability. Copaxone is indicated for reducing relapses only.
I'm curious, on what basis do you make the above statement? I thought Copaxone and Rebif had similar track records in all three categories (lesion progression, relapse reduction and progression of disablility), especially in light of Copaxone's 10-year data.
I make that statement based on the indication per both drug's package insert. The indication from the FDA is based on original pivotal trials. Rebif is the only therapy that has shown a statistically significant benefit in all three areas in their piviotal trial (per AAN Guidelines on DMD therapy). Take a look at the Copaxone package insert.
In terms of their 10 year data- this is an extension of a 2 year study that didnt even meet statistical signifcance of its endpoint at 2 years. Then the study became open label. At this point, a large majority of patients discontinued the study and ones that stayed in were patients responding well to the trial. Therefore, this is not representative of the study group as a whole- just responders.
I use the autoinjector with Copaxone and find that it is relatively painless. I am fortunate in that I rarely bruise and my site reactions are minimal. I have found that over a period of time, the stinging and site reactions became less prevalent, but I suspect this is a highly individual result.
One tip -- I have found that if I do the autoinect and then immediately jump in the shower (that's how I have arranged my morning routine), the stimulus of the shower counters the post-injection stinging sensation. It works for me.